Skip to main content
Celon Pharma S.A. logo

Celon Pharma S.A. — Investor Relations & Filings

Ticker · CLN ISIN · PLCLNPH00015 LEI · 259400Q0ERJT0NC5DT24 WAR Manufacturing
Open in API
Filings indexed 708 across all filing types
Latest filing 2025-07-16 Major Shareholding Noti…
Country PL Poland
Listing WAR CLN

About Celon Pharma S.A.

https://celonpharma.com/en/

Celon Pharma S.A. is an integrated pharmaceutical company that conducts advanced research and manufactures modern drugs. The company is engaged in the development, production, distribution, and marketing of therapeutic solutions. Its primary focus is on developing treatments for cancers, neurological diseases, diabetes, and other metabolic disorders. As a marketing authorization holder, Celon Pharma manages the full product lifecycle, from scientific research and development to commercialization, aiming to improve patient health and quality of life.

Recent filings

Filing Released Lang Actions
Otrzymanie zawiadomienia o przekroczeniu progu 5% udziału w ogólnej liczbie głosów w Spółce - Content (PL)
Major Shareholding Notification Classification · 1% confidence The document text reports that the Management Board of Celon Pharma S.A. received a notification on July 16, 2025, regarding a change in the total voting rights threshold crossed by funds managed by Tang Capital Management, LLC, exceeding 5%. This notification is explicitly stated to be pursuant to Article 69 of the Polish Public Offering Act. The content details the exact change in shareholding percentage (from 5.01% to 7.68% of capital and 3.92% to 6.01% of votes). This clearly describes a notification of a change in significant share ownership, which corresponds directly to the Major Shareholding Notification category (MRQ). The document length is very short (919 chars) and mentions that the content of the notification is attached as an appendix, but the core content provided *is* the notification summary itself, making it the primary filing type rather than just an announcement of a report (RPA/RNS).
2025-07-16 Polish
Wykaz akcjonariuszy posiadających co najmniej 5% głosów na Zwyczajnym Walnym Zgromadzeniu Celon Pharma S.A. w dniu 26 czerwca 2025 r. - Content (PL)
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document text explicitly mentions the 'Zwyczajnym Walnym Zgromadzeniu Spółki' (Annual General Meeting/Ordinary General Meeting) held on June 26, 2025, and lists the shareholders who held at least 5% of the votes and the resulting voting percentages at that meeting. This content directly relates to the results of a shareholder vote at a general meeting. Therefore, the appropriate classification is Declaration of Voting Results & Voting Rights Announcements (DVA). The document is short and reports the results directly, not announcing a future report.
2025-06-26 Polish
Uchwały podjęte przez ZWZ
AGM Information Classification · 1% confidence The document text consists entirely of resolutions ("Uchwały") passed during a "Zwyczajnego Walnego Zgromadzenia" (Ordinary General Meeting) held on June 26, 2025. The resolutions cover procedural matters (electing a chairman, approving the agenda), approval of the 2024 Annual Report and Financial Statements, dividend policy, and crucially, the granting of 'absolutorium' (discharge/vote of confidence) to members of the Management Board and Supervisory Board for their performance in the 2024 fiscal year. Documents detailing the proceedings and resolutions of an Annual General Meeting (AGM) are classified as AGM Information.
2025-06-26 Polish
Uchwały podjęte przez Zwyczajne Walne Zgromadzenie Celon Pharma S.A. w dniu 26 czerwca 2025 r. - Content (PL)
AGM Information Classification · 1% confidence The document text is very short (430 characters) and explicitly states that the Management Board ('Zarząd') is enclosing ('przekazuje w załączeniu') the content of the resolutions ('treść uchwał') adopted by the Ordinary General Meeting ('Zwyczajne Walne Zgromadzenie') held on June 26, 2025. This structure—a brief announcement transmitting the actual resolutions—strongly suggests this is an announcement about the meeting's outcome rather than the full presentation or detailed voting results document itself. Since the content relates directly to the resolutions passed at the AGM, the most appropriate classification is AGM Information (AGM-R), which covers presentations and materials shared during the AGM. Although DVA (Declaration of Voting Results) is related, AGM-R is broader for general meeting materials/outcomes.
2025-06-26 Polish
Przekazanie informacji o wprowadzeniu produktu leczniczego TIKOZEK do regulatorów rynku farmaceutycznego - Content (PL)
Regulatory Filings Classification · 1% confidence The document text is very short (890 characters) and describes a specific regulatory action: the company informing the Chief Pharmaceutical Inspector about the first-time admission to trade of a medicinal product (TIKOZEK). This is a specific regulatory notification concerning product approval/launch, not a general financial report (like 10-K or IR), an earnings release (ER), or a management change (MANG). Since there is no specific category for 'Product Regulatory Approval Notification,' and it is a formal notification to a regulatory body, it best fits the general 'Regulatory Filings' fallback category (RNS), as it is a specific, non-financial regulatory announcement.
2025-06-03 Polish
zal05_Sprawozdanie_o_wynagrodzeniach_Czlonkow_Zarzadu_i_RN_Celon_Pharma_SA_za_2024.pdf
Remuneration Information Classification · 1% confidence The document title is "SPRAWOZDANIE O WYNAGRODZENIACH CZŁONKÓW ZARZĄDU I RADY NADZORCZEJ CELON PHARMA S.A. ZA OKRES 01.01.2024. - 31.12.2024." which translates to "REPORT ON REMUNERATION OF MANAGEMENT BOARD AND SUPERVISORY BOARD MEMBERS OF CELON PHARMA S.A. FOR THE PERIOD 01.01.2024 - 31.12.2024.". The content details the remuneration structure, amounts paid to board members, and comparisons over several years, explicitly referencing Polish law regarding public offering and public companies (art. 90g of the Act). This content directly matches the definition of a Remuneration Information report, which corresponds to the filing code DEF 14A (Proxy Solicitation/Information Statement, often used for executive compensation disclosures in US context, but here mapping to the specific compensation report content). Given the specific focus on executive and board compensation, the most appropriate classification from the provided list is DEF 14A (Remuneration Information).
2025-05-30 Polish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.